{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:32:14Z","timestamp":1791660734060,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.008","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:36:46Z","timestamp":1610933806000},"page":"132-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-3844","authenticated-orcid":false,"given":"Robin L.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8493","authenticated-orcid":false,"given":"Suzanne","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-4002","authenticated-orcid":false,"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant P.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A.L.M.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.12.008_bib1","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.12.008_bib3","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in\u00a0vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","article-title":"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors","volume":"125","author":"Hirota","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2020.12.008_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdr631","article-title":"Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series","volume":"23","author":"Roubaud","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib6","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib7","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.12.008_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2020.12.008_bib9","unstructured":"Blueprint Medicines (Netherlands) B.V. AYVAKIT\u00ae (avapritinib). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ayvakyt-epar-product-information_en.pdf. [Accessed 8 October 2020]."},{"key":"10.1016\/j.ejca.2020.12.008_bib10","unstructured":"Blueprint Medicines Corporation. AYVAKIT\u00ae (avapritinib). Prescribing Information. https:\/\/www.blueprintmedicines.com\/uspi\/AYVAKIT.pdf. [Accessed 6 March 2020]."},{"key":"10.1016\/j.ejca.2020.12.008_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.12.008_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2017.02.007","article-title":"Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients","volume":"76","author":"Farag","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.008_bib14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10637-012-9795-9","article-title":"Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group","volume":"30","author":"Park","year":"2012","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2020.12.008_bib15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","article-title":"Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort","volume":"56","author":"Hompland","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib16","article-title":"Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST)","volume":"29","author":"Mv","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.008_bib18","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.12.008_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.12.008_bib20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.12.008_bib21","series-title":"Connective Tissue Oncology Society annual meeting","article-title":"Avapritinib for the treatment of GIST: analysis of efficacy, safety, and patient management strategies at the recommended phase 2 dose","author":"Joseph","year":"2019"},{"key":"10.1016\/j.ejca.2020.12.008_bib22","unstructured":"Pfizer Inc. LORBRENA (lorlatinib) tablets. Prescribing information. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=11140. [Accessed 6 March 2020]."},{"key":"10.1016\/j.ejca.2020.12.008_bib23","unstructured":"Genetech USA Inc. ROZLYTREK (entrectinib) capsules. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212725s000lbl.pdf. [Accessed 14 April 2020]."},{"key":"10.1016\/j.ejca.2020.12.008_bib24","unstructured":"US Food and Drug Administration. NDA\/BLA Multi-disciplinary review and evaluation NDA 212608 AYVAKIT (avapritinib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212608Orig1s000MultidisciplineR.pdf. [Accessed 6 March 2020]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:46Z","timestamp":1760733046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"alternative-id":["S0959804920314234"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}